T he major and most well-known function of vitamin D is to maintain calcium and phosphorus homeostasis and promote bone mineralization. However, recent research has revealed that optimal vitamin D status may be important for a variety of nonskeletal outcomes. The purpose of the review was: (1) to synthesize the available evidence on the role of vitamin D in medical conditions such as muscle function and falls, fractures, compromised immunity, glucose intolerance, and cardiovascular disease in inpatient populations, including those requiring nutrition support; (2) to review methods for assessing vitamin D status; and (3) to suggest strategies to restore vitamin D status in patients requiring enteral nutrition (EN) or parenteral nutrition (PN). 
Literature Search and Data Synthesis
We searched MEDLINE for English-language literature from 1966 through December 2008 for: (1) observational studies on the association between vitamin D status and outcomes, (2) interventional studies of the effect of vitamin D supplementation, and (3) systematic reviews or comprehensive narrative reviews on the role of vitamin D in inpatient populations with special focus among those requiring nutrition support. Search terms included diabetes, hyperglycemia, glucose, metabolic syndrome, cardiovascular disease, metabolic bone disease, fracture, falls, immune system, infection, autoimmunity, inpatient, hospital, nutrition therapy, enteral nutrition, parenteral nutrition, vitamin D, and related terms. Additional publications were identified from citations from the recovered articles, review articles, and personal reference lists, and we selected those we judged relevant.
Review of Vitamin D Homeostasis
The sources of vitamin D include cutaneous synthesis (in the form of cholecalciferol [D 3 ]) and intake (from diet and/ or supplements in the form of D 3 or, less frequently, ergocalciferol [D 2 ]). Upon exposure to solar ultraviolet B radiation (UVB), 7-dehydrocholesterol in the skin is converted to
The major and most well-known function of vitamin D is to maintain calcium and phosphorus homeostasis and promote bone mineralization. However, recent evidence suggests that vitamin D may be important for a variety of nonskeletal outcomes. The review synthesizes the available evidence for the role of vitamin D in skeletal health as well as its novel roles in medical conditions such as muscle function, falls, immunity, glucose homeostasis, and cardiovascular diseases. The article reviews methods for assessing vitamin D status and suggests strategies to restore vitamin D status in patients requiring enteral or parenteral nutrition who are at particularly high risk of hypovitaminosis D. Screening for hypovitaminosis D with plasma total 25-hydroxyvitamin D should be a routine part of the care of the patient requiring enteral or parenteral nutrition. Restoration of optimal vitamin D status with high-dose supplemental vitamin D is required in most cases, whereas exposure to sunlight or an ultraviolet B radiation-emitting device is most effective in patients with severe malabsorption or those requiring longterm parenteral therapy. Given the emerging role of vitamin D for a variety of acute and chronic conditions, the optimal vitamin D status in acutely ill patients as well as in patients requiring longprevitamin D 3 , which is immediately converted to vitamin D 3 
Assessment of Vitamin D Status
Because of its long half-life (approximately 3 weeks), plasma 25(OH)D concentration is considered the best measure for assessing vitamin D status.
1,2 Low 25(OH)D concentration has been correlated with classic conditions of vitamin D deficiency such as hypocalcemia, secondary hyperparathyroidism, rickets, and osteomalacia, whereas improvements in circulating 25(OH)D have been correlated with recovery from these conditions. 3, 4 The most widely used method to quantify 25(OH)D is radioimmunoassay. Automated direct detection methods, such as chemiluminescence, high-performance liquid chromatography, and liquid chromatography-mass spectroscopy assays have become increasingly common, especially in large medical centers. The latter 2 methods quantify and report 25(OH)D 2 and 25(OH)D 3 separately. However, it is not clear whether this separation is useful in clinical practice, as nearly all patients tested will have no detectable circulating 25(OH)D 2 unless they have been treated with ergocalciferol (D 2 ). Because there is evidence that separate reporting may confuse interpretation by physicians, 5 it is recommended that in routine clinical practice the total 25(OH)D be reported and evaluated. 6 Vitamin D binding protein decreases with injury or trauma, and reduced concentrations appear to reflect severity of illness and predict eventual morbidity or mortality. 7 In general, biochemical markers that are routinely measured in acutely or chronically ill patients are likely to be of little value in suggesting the presence of hypovitaminosis D. Serum measurements of calcium and phosphorus are influenced by many factors. In hospitalized ill patients, hypoalbuminemia has been a predictor of hypovitaminosis D in some but not all studies.
12-15 Hypophosphatemia with initiation of enteral feeding is not uncommon in hospitalized patients, especially in those at risk for refeeding syndrome. Hypovitaminosis D may impair phosphate absorption from food, EN products, and supplements. Hypophosphatemia seen during enteral feeding should stimulate consideration of assessment of vitamin D status.
Vitamin D Status in the Population
As described below, there is controversy as to the optimal 25(OH)D plasma concentration; however, most experts agree that a plasma concentration <20 ng/mL (50 nmol/L) is considered "deficiency," whereas a plasma concentration <30 ng/ mL (75 nmol/L) is considered "insufficiency." 16, 17 Data from National Health and Nutrition Examination Survey III (NHANES III) show that vitamin D insufficiency may affect the majority of the noninstitutionalized population in the United States, even in the southern latitudes during the winter. [18] [19] [20] [21] Additional studies have shown a prevalence of hypovitaminosis D ranging from 36% to 100% in a variety of populations worldwide, from healthy young adults to hospitalized elderly individuals. 12, 20, [22] [23] [24] [25] [26] [27] [28] [29] As expected, vitamin D deficiency is much more common in high-risk populations, such as homebound elderly and hospitalized persons who are sun-deprived and have suboptimal nutrition, 12, 24, 30 overweight/obese individuals, and those with dark skin such as non-Hispanic blacks and Hispanics.
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Risk Factors for Hypovitaminosis D
There are multiple risk factors for hypovitaminosis D, as outlined in Table 2 . Approximately 80% of the variation in vitamin D status among individuals can be explained by differences in cutaneous synthesis as a function of UVB exposure and skin color. 33 As 25(OH)D concentration is inversely related to body weight and body fat, 34, 35 excess body weight is another important predictor of vitamin D status. In obese patients with hypovitaminosis D, vitamin D status does not necessarily normalize after bariatric surgery, and these patients remain at risk for vitamin D deficiency, secondary hyperparathyroidism, and metabolic bone disease. 36, 37 The risk for vitamin D deficiency may be related, in part, to the degree of systemic inflammation. 38 Hospitalized patients, especially those with prolonged hospitalizations or in long-term care facilities, including those who require short-term or long-term EN or PN, are at particularly high risk for vitamin D deficiency because they exhibit many of the major risk factors, including lack of exposure to UVB light, suboptimal vitamin D intake, advanced age, and diseases or medication influencing vitamin D metabolism.
Similar to healthy individuals, hospitalized patients have an increased risk for hypovitaminosis D because of lack of sun exposure, 12, 39, 40 especially those with prolonged hospital stays. Although dietary intake of vitamin D is less important than UVB exposure in healthy individuals, the association between poor intake of vitamin D and hypovitaminosis D is heightened with inpatients. 12, 13, 40 Chronic illness prior to hospitalization may contribute to both poor intake and reduced sun exposure.
Vitamin D absorption is influenced by a number of gastrointestinal diseases. Patients with Crohn's disease 41, 42 and celiac disease 41 are at risk for hypovitaminosis D as well as long-term metabolic bone disease Vitamin D status is impaired by cholestatic liver disease such as primary biliary cirrhosis 43 and pancreatic insufficiency with its associated malabsorption (eg, cystic fibrosis 44, 45 ). Noncholestatic cirrhosis may be associated with impaired vitamin D status because loss of hepatocytes may result in reduced synthesis of 25(OH)D. However, not all studies have confirmed reductions in 25(OH) D in these patients, 14, 46 probably reflecting less advanced disease with preserved 25-hydroxylase function. Chronic kidney disease is commonly associated with hypovitaminosis D, at least in part due to reduced activity of 25(OH)D-1α-hydroxylase. Nephrotic syndrome may lead to increased urinary losses of vitamin D and vitamin D binding protein.
Vitamin D, Health Outcomes, and Implications for Hospitalized Patients
Emerging data demonstrate that the health implications of impaired vitamin D status are widespread and of potentially great clinical significance. The discovery that nearly all tissues in the body express the vitamin D receptor and that several tissues also express CYP27B1 enzyme, which allows for local production of 1,25(OH) 2 D with a paracrine effect, has provided new insights into the role of vitamin D in several medical conditions. Hypovitaminosis D has been associated with increased all-cause and cardiovascular mortality, 47 whereas a recent meta-analysis of randomized trials showed that intake of ordinary doses of vitamin D supplements was associated with a modest decrease in total mortality. 48 However, because the risk factors for vitamin D deficiency are also risk factors for many acute and chronic medical conditions, vitamin D status is an excellent marker of overall health; therefore, the observational studies linking hypovitaminosis D with suboptimal health may not reflect a true association because of potential residual or unmeasured confounding.
Musculoskeletal function
Musculoskeletal disability and falls are serious undesirable events among patients in hospitals and long-term care facilities. [49] [50] [51] Several observational studies have reported an association between vitamin D insufficiency and poor lowerextremity muscle performance, gait imbalance, and increased risk of falls. [52] [53] [54] Randomized trials have shown improvements in muscle performance after vitamin D supplementation in these patients. [55] [56] [57] [58] [59] A meta-analysis that assessed the effectiveness of vitamin D in preventing falls concluded that vitamin D supplementation reduces the risk of falls among ambulatory or institutionalized older individuals by >20%. 59 Recent trials have supported a beneficial role of supplemental vitamin D in falls 60, 61 ; however, other trials found no effect. [62] [63] [64] Two of the trials with neutral results were conducted in the outpatient setting, where the baseline incidence of falls is low. Vitamin D is thought to improve muscle function via a direct effect on myocytes, which express vitamin D receptors. 65 Evidence of the effect of vitamin D on bone health and fractures varies between studies. An evidence-based review combining data from 13 trials found a nonsignificant reduction in fractures but significant heterogeneity between studies. 66 The effect appears to be maximal when high-dose vitamin D (700-800 IU [17.5-20 µg]/d) is given in older persons living in institutionalized settings.
Vitamin D deficiency is associated with osteomalacia, which in adults presents with nonspecific complaints of malaise, fatigue, and body aches, and can be debilitating to the patient and frustrating for the clinician to diagnose. Restoring vitamin D status can reverse symptoms of osteomalacia.
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Metabolic bone disease
A chronic complication in patients receiving PN is the occurrence of metabolic bone disease. This has been reported in the majority of patients receiving long-term home PN. 68 Several factors have been implicated in the cause of PN-associated metabolic bone disease, including calcium deficiency, aluminum toxicity, and the contribution by crystalline amino-acid solutions. The role of vitamin D in the pathogenesis of PN-associated metabolic bone disease has been controversial. It has been suggested that in the absence of a requirement for enteral calcium absorption, the amount of exogenous vitamin D found in the injectable multivitamin package may be toxic to the bone. It has been hypothesized that in those patients with suppressed PTH, provision of parenteral vitamin D contributes to metabolic bone disease. 68 In 2 studies, withdrawal of vitamin D from PN was associated with improvement in the clinical and biochemical indices of bone mineralization. 69, 70 In these studies, vitamin D status, as assessed by 25(OH)D level, was suboptimal by current criteria. No reports in the last decade have confirmed these findings. In a recent study, bone mineral loss in patients receiving long-term PN was similar in age-and gendermatched controls, 71 suggesting that underlying disease itself may be responsible for metabolic bone disease and PN is less likely to promote metabolic bone disease.
Immune system, infections, and autoimmunity
Hospital-acquired infections are prevalent in hospitals and long-term facilities. Hospitalized patients are exposed to a large number of pathogens, and the risk of acquiring an infection increases when immunity is compromised. Several lines of evidence suggest an important role of vitamin D as a regulator of the immune system. 72 Therefore, a patient's preadmission vitamin D status may affect the risk and severity of hospital-acquired infections. In observational studies, vitamin D deficiency has been found to be associated with development of infections, including influenza and tuberculosis. 73, 74 Infants with rickets are at increased risk for respiratory infection. 75, 76 There are limited data from randomized trials to suggest that vitamin D supplementation may prevent infections. 77, 78 A direct role of vitamin D in immunity is suggested by the expression of the vitamin D receptor by the majority of immune cells, including antigen-presenting cells like macrophages and dendritic cells, as well as activated CD4 and CD8 T lymphocytes. 79 Moreover, macrophages express CYP27B1, which allows local synthesis of the active form of vitamin D. 72, 80 These findings suggest a fundamental role of vitamin D in the innate immune system and a potentially important role in preventing infections among susceptible individuals, including those who required long-term EN or PN therapy. Finally, several studies have reported an association between hypovitaminosis D and a variety of autoimmune diseases, including type 1 diabetes mellitus, multiple sclerosis, inflammatory bowel disease, and rheumatoid arthritis. [81] [82] [83] [84] Vitamin D is thought to act as an immunomodulator by suppressing T-helper type 1 cytokine profile, which favors suppressor T cells (T-helper type 2).
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Glucose homeostasis and cardiovascular disease
Diabetes and cardiovascular disease (hereafter termed cardiometabolic disease) are major causes of morbidity and mortality in the industrialized world. On the basis of evidence from animal and human studies, vitamin D has emerged as a potential modifier of cardiometabolic risk. 86 Vitamin D insufficiency has long been suspected to be a risk factor for type 1 diabetes. 87 Accumulating evidence suggests that altered vitamin D homeostasis may play a role in the development of type 2 diabetes and cardiovascular disease. Observational studies have reported a consistent association between hypovitaminosis D and incident type 2 diabetes 88 or cardiovascular disease. 47, 89, 90 Evidence from randomized trials on cardiometabolic disease is limited. A posthoc analysis of a trial designed for bone-related outcomes showed a beneficial effect of combined vitamin D 3 (700 IU [17.5 µg]/d) and calcium (500 mg/d) supplementation on preventing the worsening of glucose intolerance among nondiabetic adults with altered glucose homeostasis at baseline. 91 However, a posthoc analysis from the large Women's Health Initiative trial showed no effect of combined vitamin D 3 (400 IU [10 µg]/d) and calcium (1,000 mg/d) supplementation on incident cardiovascular disease 92 or self-reported diabetes. 93 In the Women's Health Initiative, the neutral results may be explained by the low dose of supplemental vitamin D 3 , which is considered insufficient for both skeletal and nonskeletal outcomes. Congestive heart failure has been associated with increased risk for hypovitaminosis D. 94, 95 Patients with congestive heart failure supplemented with 2,000 IU of vitamin D 3 showed reduced concentrations of inflammatory cytokines, although it remains unclear whether this could translate to improved myocardial function or delayed disease progress. 96 Several ongoing trials are expected to offer further insights into the role of vitamin D on cardiometabolic disease. The potential effects of vitamin D on the cardiometabolic system are thought to be mediated by a variety of mechanisms, including improving pancreatic β-cell function, enhancing insulin action in insulin-sensitive tissues, ameliorating systemic inflammation, regulating smooth muscle function, and inhibiting the renin-angiotensin system.
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Vitamin D Supplementation
The Food and Nutrition Board of the Institute of Medicine set the adequate intake of vitamin D at 200-600 IU (5-15 µg)/d based on age. 3 In the Nurses' Health Study, a large prospective observational cohort, it was found that only 3% of female nurses reported the recommended vitamin D intake for their age. However, there is growing consensus that vitamin D intakes above these levels are associated with better health outcomes. Optimal plasma 25(OH)D concentration is highly debatable. But for a variety of skeletal and nonskeletal outcomes, most experts agree that a plasma concentration >30 ng/mL (75 nmol/L) is required to improve outcomes. 97 To achieve this desired level of 25(OH) D, an intake of at least 1,000 IU [25 µg 100 Effective supplementation can be achieved on a daily, weekly, or monthly basis. 101 The amount of vitamin D in commonly used EN formulations (Table 3) is consistent with the official recommendations by the Food and Nutrition Board. 3 However, ill patients will likely need much higher intakes of vitamin D because of aging, lack of sun exposure, and other factors such as malabsorptive syndromes or renal disease.
Our recommendation is to first confirm hypovitaminosis D (plasma 25 Given the lack of requirement for calcium absorption, patients who are exclusively receiving PN do not require vitamin D for calcium absorption; however, given the direct effects of vitamin D on parathyroid cells and osteocytes, and its pleiotropic effects on tissues not involved in calcium homeostasis, maintaining optimal vitamin D levels is important in this population as well. The difficulty with patients requiring PN is determining the optimal level of 25(OH) 2 D concentration. In patients requiring long-term PN, frequent (eg, monthly) measurements of 25(OH)D, 1,25(OH) 2 D, PTH, and calcium and maintenance of these markers as close to normal as possible are important. Vitamin D supplementation in patients who require PN is also challenging because of the lack of a high-dose (eg, 50,000 IU) parenteral formulation of vitamin D. Currently, patients receiving PN receive a daily multivitamin injection that contains 200-400 IU (5-10 µg) of vitamin D 2 or D 3 , depending on the product. There is an intramuscular form of high-dose vitamin D 2 , but it is not available in the United States. The intramuscular form may not provide consistency in solubility and absorption profile to result in a predictable clinical response and can cause significant discomfort; therefore, it is not recommended. An alternative and quite effective method to improve vitamin D status in individuals with malabsorption syndromes and those on long-term PN is exposure to sunlight or UVB radiation from a tanning bed or other UVB-emitting device. 102 On rare occasions such as with hypercalcemia or hypervitaminosis D, elimination of vitamin D from PN may be desired; however, vitamin D is included as a standard component of parenteral multivitamins and there is no known multivitamin preparation for infusion that does not contain vitamin D.
Conclusions
Vitamin D deficiency or insufficiency is very common, especially among hospitalized patients requiring longterm EN or PN, and it is associated with increased risk for a variety of acute and chronic medical conditions, including musculoskeletal disease, fractures, infection, and cardiometabolic disease. Screening for vitamin D deficiency with plasma 25(OH)D concentrations should be a routine part of the care of the patient requiring EN or PN support. Restoration of optimal vitamin D status with high-dose supplemental vitamin D is required in most cases, whereas exposure to sunlight or UVB-emitting device could be most effective in patients with severe malabsorption or those requiring long-term PN. Several unresolved questions need further investigation, including the role of vitamin D in the pathogenesis of PN-associated metabolic bone disease; the optimal plasma 25(OH)D concentration in patients requiring nutrition support, especially among those exclusively on long-term PN; and the best modality for restoring vitamin D status. Given the emerging roles for vitamin D in inflammation and glucose homeostasis, the influence of vitamin D status and vitamin D provision on outcomes in hospitalized patients deserves further attention. 
